Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA blinks

FDA has effectively blocked a pathway that was widely expected, both within the agency and in industry, to provide opportunities to market follow-on versions of proteins that are regulated as drugs. By deferring a decision on approval of Sandoz's Omnitrope human growth hormone (hGH), the agency handed a victory to that portion of the industry that has been fighting

Read the full 590 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE